A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use

Change in tumor size estimated using longitudinal tumor growth inhibition (TGI) modeling is an early predictive biomarker of clinical outcomes for multiple cancer types. We present the application of TGI modeling for subjects with multiple myeloma (MM). Longitudinal time course changes in M‐protein...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:CPT Pharmacometrics Syst Pharmacol
Asıl Yazarlar: Jonsson, F, Ou, Y, Claret, L, Siegel, D, Jagannath, S, Vij, R, Badros, A, Aggarwal, S, Bruno, R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2015
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4759707/
https://ncbi.nlm.nih.gov/pubmed/26904385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12044
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller